Navigation Links
ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits
Date:9/22/2009

SALEM, N.H., Sept. 22 /PRNewswire/ -- ALPCO is pleased to introduce a pair of ELISA kits for research use only for the easy and accurate measurement of both active (7-36) GLP-1 and combined (7-36 and 9-36) GLP-1 fragments.

GLP-1, an incretin hormone, has been a focus of the diabetes & obesity research community recently. The first incretin therapy was approved by the FDA in 2006, and early clinical data demonstrates that these therapies are delivering good results for some patients with Type II diabetes. As more incretin-based drugs are identified and proceed through the clinical development process, the area of research that focuses on elucidating the physiological impact of incretin hormones has taken on greater significance. Craig LaMarca, a scientist and technical sales advisor at ALPCO, points out: "Basic science researchers are establishing mechanisms and principles for why GLP-1 is an attractive therapeutic target. Along these same lines, but further down in the process are pharmaceutical companies who are trying to establish the functionality of potential drug candidates in their ability to increase circulating levels of GLP-1... Although most of the work currently is focusing on diabetes, recent research has implied utility of targeting GLP-1 in other therapeutic areas." For example, studies have shown that GLP-1 agonists and/or DPP-IV inhibitors offer Beta cell protection in rodents(1) - an indication that the same may be accomplished in humans, offering the hope of altering the progression of Type II diabetes. On the other hand, studies have also proposed that there is a cardioprotective and vasodilatory role for the 9-36 fragment, a peptide once thought to be relatively biologically inactive(2).

These efforts are currently hampered by a lack of good tools, as we are reminded by Mr. LaMarca: "With all of the drug development and basic research efforts ongoing, there is no accessible commercial method for quantification of circulating GLP-1, either in its active or total form. Researchers have been forced to use assays that have several systemic issues including: lack of reproducibility, inability to detect significant physiological shifts of GLP-1 resulting from meal tolerance or therapeutic intervention and lack of sensitivity. Since fasting levels are so low, researchers are often unable to establish a baseline."

Marking a turning point in GLP-1 ELISA technology, the ALPCO/Epitope ELISA answers the need for a reproducible, highly sensitive assay to measure Active (7-36) GLP-1. This offering is enhanced by a corresponding method for detecting combined (7-36 and 9-36) fragments. The Active (7-36) assay is sensitive to 0.2 pmol/l, allowing researchers to discern low baseline values. Additionally, both kits demonstrate a marked stimulation index for fed versus fasted samples, a capability that has been lacking for commercial kits previously available to researchers.

(1) Suarez-Pinon W, et al. 2008. Diabetes; 57 (12): 3281-3288.

(2) Ban K, et al. 2008. Circulation; 117: 2340-2350

Media contact: Kate Kaplan, 1-800-592-5726 x220


'/>"/>
SOURCE ALPCO
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: